Trials / Completed
CompletedNCT03208933
Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).
Local Open-label Multicenter Study to Assess the Effectiveness of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis in Russian Clinical Practice
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study is a national, multicenter, interventional, non-randomized, non-controlled, open-label study to assess the effectiveness of pirfenidone in participants with IPF in Russian clinical practice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pirfenidone | Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days. |
Timeline
- Start date
- 2017-10-23
- Primary completion
- 2019-11-13
- Completion
- 2019-11-13
- First posted
- 2017-07-06
- Last updated
- 2020-11-20
- Results posted
- 2020-11-20
Locations
11 sites across 1 country: Russia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03208933. Inclusion in this directory is not an endorsement.